Research Paper Volume 13, Issue 2 pp 2436—2458

Figure 5. FX5 treatment improved glucose homeostasis in db/db and HFD/STZ-induced T2DM mice. (A) db/db mice were divided into three groups (n=10/group), and treated with vehicle (Veh), FX5 (30 mg/kg) or FX5 (60 mg/kg) once per day for 5 weeks. Plasma glucose concentration after 6 h fasting was measured weekly. (B) After 5-week administration, HbA1c level of db/db mice in three groups was detected. (C) OGTT result and (D) AUC result of OGTT in db/db mice. (E) PTT result and (F) AUC result of PTT in db/db mice. (G) HFD/STZ-induced T2DM mice were divided into three groups (n≥7/group) and treated with vehicle (Veh), FX5 (30 mg/kg) or FX5 (60 mg/kg) for 5 weeks. Plasma glucose concentration after 6 h fasting was measured weekly. (H) After 5-week administration, HbA1c level of HFD/STZ mice in three groups was detected. (I) OGTT result and (J) AUC result of OGTT in HFD/STZ-induced T2DM mice. (K) PTT result and (L) AUC result of PTT in HFD/STZ-induced T2DM mice. In all line graphs, black for vehicle (Veh), blue for FX5 (30 mg/kg) and red for FX5 (60 mg/kg). Values were shown as mean± S.E.M (*P<0.05, **P<0.01 and ***P<0.001).